RadNet Inc (RDNT)

Cardiac AI Diagnostics Stack Validation Wins Across Regulatory and Commercial FrontsMay 19, 2026 8:55 AM
PR Newswire (US) Issued on behalf of Ventripoint Diagnostics Ltd.A Toronto-based small-cap is converting clinical validation into real-world hospital deployments at the moment AI cardiac imaging procurement is reorganizing globallyNEW YORK, May 19, 2026 /PRNewswire/ -- USA News Group News Commentary — Cardiology has become one of the proving grounds for medical artificial intelligence, and the procurement environment around it has shifted hard in the last twelve months. Hospital networks are no longer content to evaluate clinical accuracy in isolation; they want department-level economic proof before they sign deployment contracts. That shift is reshaping which AI imaging companies can convert pilot data into recurring revenue, and which cannot. The companies winning right now are the ones stacking regulatory clearances, commercial partnerships, and reimbursement-friendly clinical evidence at the same time. Industry forecasts help frame the prize at stake. The artificial intelligence in cardiology market has been projected to grow from approximately US$2.78 billion in 2026 to roughly US$14.22 billion by 2034, representing a compound annual growth rate near 22.6% over the period.[1] Echocardiography alone — the most widely used cardiac imaging modality in the world — is forecast to expand to US$2.64 billion by 2030 as health systems demand cardiac platforms that prove economic value alongside clinical accuracy.[2]Read the full report of Ventripoint here: USA News Group Ventrpoint CoveragePortable ultrasound, valued at roughly US$2.79 billion in 2026, is pushing cardiac assessment beyond the imaging lab and into point-of-care settings where speed and cost efficiency determine which technologies earn long-term hospital contracts.[3]Inside that environment, Ventripoint Diagnostics Ltd. (TSXV: VPT) (OTC: VPTDF) has spent the first half of 2026 stringing together exactly the kinds of validation events that the new procurement environment rewards.The Toronto-headquartered company applies proprietary Knowledge Based Reconstruction technology to standard 2D echocardiograms and produces volumetric cardiac measurements that the company describes as equivalent in accuracy to magnetic resonance imaging — and it does so on ultrasound systems that already sit in hospitals worldwide, regardless of vendor.A Regulatory Submission Into the World's Largest Cardiac Disease PopulationOn April 28, 2026, Ventripoint announced that its strategic partner Lishman Global Inc. had formally submitted the Company's VMS+ 4.0 system to China's National Medical Products Administration (NMPA) — the regulatory body commonly referred to as the Chinese FDA — for approval.[4] The filing is the principal regulatory gating event for VMS+ access to the Chinese cardiology market, and according to the Company, Lishman Global qualified for the NMPA's "green channel" pathway, an expedited review process designed for innovative medical technologies that address significant clinical needs.[4]The scale of the opportunity is difficult to overstate. The Company has cited an estimated 330 million cardiovascular disease patients in China, with cardiovascular disease the leading cause of mortality in the country.[4]Echocardiography is already the most widely used cardiac imaging modality in China because of its cost-effectiveness, portability, and scalability across both urban and rural healthcare settings.[4] What the market has been short on, in Ventripoint's framing, is the kind of AI-driven analytic layer that produces consistent, MRI-equivalent volumetric measurements from those existing ultrasound exams — particularly given variability in image interpretation across operators and limited access to advanced modalities like MRI in many parts of the country."China is one of the most important cardiac care markets in the world," said Hugh MacNaught, President and Chief Executive Officer of Ventripoint Diagnostics, in the announcement. "With the benefit of an expedited review pathway, we are well positioned to bring VMS+ 4.0 to clinicians and patients more quickly."[4] Paul Gibson, Chief Technology Officer of Lishman Global, added that qualification for the NMPA's green channel "underscores the clinical relevance and innovation of VMS+ 4.0 and provides a clear pathway to accelerated adoption."[4]Read the full report of Ventripoint here: USA News Group Ventrpoint CoverageBringing AI Cardiac Imaging Into a Padua-Based European CongressSix days after the NMPA submission was announced, Ventripoint disclosed plans to exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC), held May 12–16, 2026 in Padua, Italy.[5] Founded in 1963, AEPC is described as the world's largest association in congenital cardiology, bringing together more than 1,000 specialists across 32 European countries.[5]The 2026 meeting was hosted by the University of Padova and featured a scientific program centred on advanced cardiovascular imaging and artificial intelligence — a fit, the Company argued, for what VMS+ is designed to deliver.[5]A central focus of Ventripoint's booth at AEPC was the use of VMS+ to support evolution of cardiac function over time in congenital heart disease (CHD) patients. The clinical rationale, as the Company described it, sits inside the 2020 ESC Guidelines for Adult Congenital Heart Disease — guidelines co-endorsed by AEPC — which identify CHD as a lifelong chronic condition requiring structured, individualised follow-up, and which affirm echocardiography as the key modality for longitudinal assessment of ventricular function.[5] The latest release, VMS+ 4.0, was purpose-built around the workflow needs of clinicians, the Company has said, streamlining the time required to generate assessments and making volumetric cardiac analysis accessible at the point of care.[5]"AEPC represents the heart of the European congenital cardiology community, and we are proud to be part of it," MacNaught said in the AEPC announcement. "VMS+ delivers fast, affordable, and accessible volumetric cardiac assessments with accuracy comparable to MRI — giving clinicians the confidence they need to manage their patients at every stage of life."[5]A Wider Pattern of Validation Events Through Spring 2026The NMPA submission and AEPC exhibition are the two most recent links in a chain of events the Company has been building since the start of the year. Earlier in spring 2026, Ventripoint announced its Edison Award recognition, signed a commercial agreement with LG Consulting Solutions to support deployment of VMS+ across Northern California hospital systems, and announced a partnership delivering AI 3D heart mapping into Indigenous community settings through a Nisg_a'a partnership.[6]Considered together, those steps describe a small-cap AI medtech company simultaneously stacking validation across regulatory, commercial, and clinical fronts at the exact moment the broader hospital procurement environment is reorganizing around AI clinical solutions.[6]The LG Consulting Solutions agreement is structured precisely to address the financial proof requirement that has come to dominate hospital adoption decisions. Under the agreement, LG Consulting provides economic analysis, clinical implementation support, and health system business case development to assist hospitals and cardiac programs in adopting VentriPoint's AI-enhanced echocardiography technology.[6]In other words, the commercial framework on the ground in Northern California is designed to deliver department-level economic justification — which is exactly what hospital procurement is currently demanding before they sign.How Ventripoint Sits Inside a Reshaping Cardiac AI FieldVentripoint is far from the only public company chasing the AI cardiac imaging opportunity. Several larger names have moved aggressively across the past year — and the procurement environment for AI medtech is reshaping in real time as a result.Butterfly Network, Inc. (NYSE: BFLY) is one of the highest-profile names in handheld ultrasound. The Company has continued to expand integrations between its iQ family of probes and third-party AI cardiac applications, including the August 2025 announcement integrating Bordeaux-based DESKi's HeartFocus cardiac examination software into Butterfly's handheld devices — software that received FDA clearance in April 2025 and that allows healthcare professionals with minimal training to capture complete echocardiographic views.[7] Butterfly's strategy of partnering with AI cardiac software vendors places it in a structurally adjacent — but distinct — segment of the cardiac AI market from a knowledge-based reconstruction platform like Ventripoint's VMS+.Tempus AI, Inc. (NASDAQ: TEM) has been one of the cardiology AI sector's most-watched commercial stories. Tempus generated $1.2 billion in revenue for full-year 2025 and issued 2026 guidance of approximately $1.59 billion with around $65 million in adjusted EBITDA — projecting its first year of positive adjusted profitability.[1] Tempus's platform integrates genomic sequencing, clinical data analytics, and AI-driven insights across oncology, cardiology, and neuropsychiatric care — a substantially broader footprint than a pure-play cardiac imaging company, but one that frames the institutional investor appetite for AI medical platforms more generally. RadNet, Inc. (NASDAQ: RDNT) has built one of the larger imaging-services-plus-AI businesses through its DeepHealth subsidiary. RadNet's recent acquisition of Gleamer — whose products are deployed in over 2,000 facilities across 30 countries — uniquely positions DeepHealth to expand its impact across routine imaging and accelerate the delivery of automated diagnostics, with the combined entity projected to generate approximately $30 million in annualized recurring AI revenue in 2026.[1] RadNet's scale on the imaging-services side gives it a different kind of moat than a pure software vendor — but the strategic message about AI moving from pilot to recurring revenue is the same one playing out across the sector.GE HealthCare Technologies Inc. (NASDAQ: GEHC) brings the perspective of one of the world's largest installed bases of cardiac imaging equipment. GE HealthCare has been advancing its own cardiac imaging capabilities through AI-powered reconstruction technologies — including AIR Recon DL and Sonic DL — designed to deliver diagnostic-quality cardiac MRI scans in significantly reduced timeframes.[1]The fact that the largest incumbent in the space is investing aggressively in AI-augmented cardiac imaging is, if anything, supportive of the thesis that AI-enhanced echocardiography platforms like Ventripoint's are arriving into a market actively being reorganized around AI-driven clinical workflows. Across all four comparables, the same pattern shows up: hospital systems are demanding economic proof, AI cardiac imaging is shifting from pilot to recurring revenue, and AI-augmented echocardiography is increasingly viewed as the most leverageable cardiac modality given its existing scale, portability, and cost profile.What Comes NextVentripoint's near-term catalysts are reasonably visible. The NMPA review process for VMS+ 4.0 in China is now underway, and the Company has said it will provide further updates as the review process progresses.[4] On the commercial side, the LG Consulting Solutions deployment partnership in Northern California is set up to convert clinical evidence into hospital-level economic justification.[6] On the European side, the AEPC exhibition in Padua delivered direct engagement with the largest concentration of paediatric and congenital cardiologists in Europe — a clinical community uniquely well-suited to longitudinal echocardiography-driven follow-up of complex patients.[5]The Company's stated 2026 priority is accelerating the integration of VMS+ into routine clinical practice and identifying opportunities to build better care pathways for CHD patients.[5]For investors tracking the cardiac AI sector, the Company offers a small-cap exposure to a corner of the AI medtech market where the procurement environment, the regulatory environment, and the clinical evidence base have all moved into alignment within the past six months. Whether that alignment translates into accelerating commercial momentum will be measured one deployment, one NMPA decision, and one congress at a time across the back half of 2026.Read the full report of Ventripoint here: USA News Group Ventrpoint CoverageCONTACT INFORMATION
USA News Group
info @therooster-2873Article Sources
[1] https://www.fortunebusinessinsights.com/ai-in-cardiology-market-115767 [2] https://www.marketresearch.com/Business-Research-Company-v4006/Cardiac-AI-Monitoring-Diagnostics-Global-44014609/ [3] https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-in-cardiology-market-report [4] https://finance.yahoo.com/sectors/healthcare/articles/ventripoints-vms-tm-4-0-120000052.html [5] https://finance.yahoo.com/sectors/healthcare/articles/ventripoint-exhibit-59th-annual-meeting-132316747.html [6] https://www.globenewswire.com/news-release/2026/05/13/3294035/0/en/A-Toronto-AI-Cardiac-Diagnostics-Company-Just-Cleared-Three-of-the-Hardest-Validation-Bars-in-Medtech.html [7] https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-in-cardiology-market-reportDISCLAIMER NOTICENothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (MIQ). This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Ventripoint Diagnostics Ltd. advertising or digital media, but the owner/operators of MIQ also co-owns Baystreet.ca Media Corp. (BAY) There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.Logo - https://mma.prnewswire.com/media/2838876/5656770/USA_News_Group_Logo.jpg View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiac-ai-diagnostics-stack-validation-wins-across-regulatory-and-commercial-fronts-302775850.htmlSOURCE USA News Group Original: Cardiac AI Diagnostics Stack Validation Wins Across Regulatory and Commercial Fronts

Hospital Networks Turn to AI-Enhanced Cardiac Imaging to Cut Costs and Improve OutcomesMarch 3, 2026 12:19 PM
PR Newswire (US)

Issued on behalf of VentriPoint Diagnostics Ltd.VANCOUVER, BC, March 3, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary — AI is making its way through the halls of our entire medical system, and the implementation is accelerating at a great pace. The AI medical imaging market is projected to hit nearly $20 billion by 2033, growing at a 34.7% CAGR[1]. Echocardiography alone is forecast to grow to $2.64 billion by 2030 as hospitals demand cardiac platforms that prove economic value alongside clinical accuracy[2]. Companies like VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Butterfly Network (NYSE: BFLY), Tempus AI (NASDAQ: TEM), RadNet (NASDAQ: RDNT), and GE HealthCare (NASDAQ: GEHC) are converting clinical validation into contracted hospital deployments.







Digital diagnostics platforms are projected to reach $7.67 billion by 2035 at an 18.12% CAGR as health systems shift from evaluating clinical capability to requiring department-level financial proof before adoption[3]. Portable ultrasound, valued at $2.79 billion in 2026, is pushing cardiac assessment beyond traditional imaging labs and into point-of-care settings where speed and cost efficiency determine which technologies earn long-term hospital contracts[4].VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF) recently signed a commercial agreement with LG Consulting Solutions to support deployment of its VMS+™ system across Northern California. Under the agreement, LG Consulting will provide economic analysis, clinical implementation support, and health system business case development to assist hospitals and cardiac programs in adopting VentriPoint's AI-enhanced echocardiography technology. The collaboration will focus on demonstrating the economic and clinical value of VMS+™ imaging and workflow integration across healthcare systems in the Sacramento and San Francisco regions.As part of the agreement, LG Consulting Solutions is purchasing a VMS+™ system for deployment as a demonstration platform to support hospital engagement, clinician training, and economic value assessments. The agreement also includes the potential for revenue sharing related to 3D echocardiography processing services."Economic and operational clarity are critical to accelerating the adoption of new medical technologies," said Hugh MacNaught, President and CEO of VentriPoint Diagnostics. "This collaboration will help hospitals clearly evaluate how VMS+™ can improve cardiac care pathways, enhance clinical insight into cardiac function, and support better patient care while delivering measurable value to healthcare systems."Northern California represents an important market for VentriPoint given its concentration of leading cardiac centers and healthcare systems focused on improving cardiovascular outcomes."Healthcare systems increasingly require clear clinical and economic evidence before adopting new technologies," said Lori Gallian, Principal of LG Consulting. "Through this collaboration, we will work directly with cardiac programs to develop practical implementation strategies and demonstrate how VMS+™ can deliver both clinical and operational benefits."CONTINUED… Read this and more news for VentriPoint Diagnostics at: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint In other industry developments and happenings in the market include:Butterfly Network (NYSE: BFLY) recently reported fourth quarter 2025 revenue of $31.5 million, a 41% increase year-over-year, while generating positive operating cash flow for the first time in the company's history. Full-year 2025 revenue reached $97.6 million, up 19% from the prior year. The company also launched Compass, its AI-powered clinical decision support system designed to guide clinicians through point-of-care ultrasound exams." Nearly two years into our strategic plan, we are executing with financial discipline, strengthening our core point-of-care business, and now realizing material organic revenue from new initiatives," said Joseph DeVivo, CEO of Butterfly Network. "From expanding enterprise adoption in point-of-care, to building HomeCare into a commercial business, to enabling entirely new applications through Butterfly Embedded, it's all powered by the same proprietary Ultrasound-on-Chip™ technology. One platform and one diversified strategy that puts us in a strong position to execute and win."The company issued 2026 revenue guidance of $117 million to $121 million, representing 20% to 24% growth. Butterfly's handheld ultrasound platform is used across emergency, primary care, and critical care settings, expanding cardiac and vascular assessment beyond traditional imaging labs.Tempus AI (NASDAQ: TEM) recently reported fourth quarter 2025 revenue of $367.2 million, an 83% increase year-over-year. For the full year, Tempus generated $1.2 billion in revenue and issued 2026 guidance of approximately $1.59 billion with around $65 million in adjusted EBITDA, projecting its first year of positive adjusted profitability."In 2025, Tempus continued to set the standard for what it means to be a technology company operating in the healthcare space," said Eric Lefkofsky, Founder and CEO of Tempus. "The strength of our unit growth in diagnostics along with the accelerating growth of our data business is proof that we are unique in this space. As the network effects from our investments in AI continue to compound, we expect to not only drive significant growth over the next several years, but to also enhance the lives of millions of patients around the world."The company's platform integrates genomic sequencing, clinical data analytics, and AI-driven insights across oncology, cardiology, and neuropsychiatry. Tempus serves more than 50% of U.S. oncologists and is expanding its data licensing and clinical trial matching capabilities into cardiovascular diagnostics.RadNet (NASDAQ: RDNT) recently acquired Gleamer, a Paris-based pioneer in AI-powered medical imaging, for up to €230 million. The acquisition positions RadNet's DeepHealth subsidiary as the largest radiology-focused clinical AI provider worldwide, combining Gleamer's BoneView and ChestView FDA-cleared algorithms with DeepHealth's existing suite of mammography, lung, and prostate AI solutions."As imaging volumes continue to rise amid an accelerating shortage of radiologists worldwide, reengineering high-volume workflows — particularly routine imaging such as X-ray, ultrasound and mammography — is becoming essential to sustaining access, efficiency and quality of care," said Dr. Howard Berger, President and CEO of RadNet. "For radiologists and providers, the key lies in advancing automated exam prioritization and draft reporting. The acquisition of Gleamer uniquely positions DeepHealth to expand its impact across routine imaging and high-impact acute diagnostic care and accelerate the delivery of automated diagnostics."Gleamer's products are deployed in over 2,000 facilities across 30 countries. The combined entity is projected to generate approximately $30 million in annualized recurring AI revenue in 2026, with commercial deployment spanning bone fracture detection, chest pathology screening, and advanced mammography analytics.GE HealthCare (NASDAQ: GEHC) recently announced the first implementation of its SIGNA Sprint Elite MRI system at Inova Health System. The platform integrates advanced cardiac imaging capabilities with AI-powered reconstruction technologies including AIR Recon DL and Sonic DL, designed to deliver diagnostic-quality cardiac MRI scans in significantly reduced timeframes."Achieving FDA clearance of our next-generation SIGNA MRI technology underscores our commitment to expanding access to high-quality imaging and elevating the standard of care for patients everywhere," said Kelly Londy, President and CEO, MR at GE HealthCare. "As MRI demand continues to rise across clinical areas, providers need solutions that deliver greater efficiency without compromising diagnostic precision. With this new SIGNA generation, we're redefining what's possible – aiming to bring smarter, faster, more sustainable and more consistent imaging to more patients, across more settings, with confidence."The SIGNA Sprint Elite features a compact 22-square-meter footprint, allowing installation in outpatient and community settings previously limited to basic imaging. GE HealthCare's broader imaging portfolio serves more than 1 billion patients annually across 160 countries, with its MR division focused on expanding AI-integrated cardiac and neurological imaging platforms.Article Source: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint CONTACT:USA NEWS GROUPinfo @acblanke1DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Ventripoint Diagnostics Ltd. advertising or digital media, but the owner/operators of MIQ also co-owns Baystreet.ca Media Corp. ("BAY") There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.SOURCES:https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-medical-imaging-markethttps://www.precedenceresearch.com/echocardiography-markethttps://www.towardshealthcare.com/insights/digital-diagnostics-system-market-sizinghttps://www.towardshealthcare.com/insights/portable-ultrasound-market-sizingLogo: https://mma.prnewswire.com/media/2838876/5833576/USA_News_Group_Logo.jpg



View original content to download multimedia:https://www.prnewswire.com/news-releases/hospital-networks-turn-to-ai-enhanced-cardiac-imaging-to-cut-costs-and-improve-outcomes-302702775.html

Original: Hospital Networks Turn to AI-Enhanced Cardiac Imaging to Cut Costs and Improve Outcomes

RadNet shares gain 3% following $270 million acquisition of AI firm GleamerMarch 2, 2026 7:52 AM
IH Market News
RadNet Inc (NASDAQ:RDNT) shares rose 3% to $71.91 in premarket trading on Monday after the U.S.-based imaging services provider announced plans to acquire French radiology artificial intelligence company Gleamer in an all-cash deal valued at up to €230 million ($270 million).The transaction will position RadNet’s DeepHealth division as the largest global supplier of clinical radiology AI solutions, with a customer base exceeding 2,700 organisations across more than 50 countries, the company said.Founded in 2017, Gleamer is projected to generate approximately $30 million in annual recurring revenue by 2026. RadNet noted that the company’s AI platform currently supports more than 25 clinical imaging applications.According to RadNet, integrating Gleamer’s technology is expected to help alleviate shortages of radiologists while improving workflow efficiency and reducing costs, with benefits anticipated by the third quarter of 2026.The two companies plan to showcase their combined product pipeline at this week’s European Congress of Radiology in Vienna.

Original: RadNet shares gain 3% following $270 million acquisition of AI firm Gleamer

AI Medical Imaging Revolution: Software-Native Tech Disrupts $45B MarketJanuary 27, 2026 3:14 PM
PR Newswire (Canada)

ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.VANCOUVER, BC, Jan. 27, 2026 /CNW/ -- USANewsGroup.com News Commentary – The global medical imaging market hit a massive $45.5 billion in 2026[1], marking a total structural shift toward AI-native precision as advanced cancer therapies demand more intense heart monitoring than ever before[2]. Hospitals are ditching expensive, bulky hardware for agile, cloud-based platforms that deliver MRI-quality results without the MRI-sized price tag. This pivot has catapulted the cardiac AI diagnostic sector to $2.22 billion this year[3], driven by a desperate need for continuous imaging to catch heart dysfunction caused by cancer treatments[4]. This high-stakes convergence positions VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Butterfly Network (NYSE: BFLY), RadNet (NASDAQ: RDNT), Nanox Imaging (NASDAQ: NNOX), and OneMedNet (NASDAQ: ONMD) as the essential engineering nodes where software-defined 3D modeling finally solves radiologist shortages.







Leading programs at institutions like the Mayo Clinic are proving that subscription-based imaging is the ultimate "cheat code" for patient care, turning diagnostic accuracy into measurable ROI through Device-as-a-Service frameworks[5]. By using cloud-enabled solutions to manage complex heart risks, these companies are building high-margin, recurring revenue streams that align perfectly with the new world of value-based care. This isn't just a tech upgrade; it's a total reimagining of how the world tracks heart health for life.Ventripoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF) is building a subscription business around technology that converts standard 2D ultrasound images into detailed 3D heart models with MRI-level accuracy. The system delivers precise cardiac assessments at a fraction of the cost and complexity of traditional MRI imaging.Strong investor demand recently doubled the company's private placement from $500,000 to $1 million. The capital will fund commercialization activities, manufacturing scale-up, regulatory submissions across additional markets, and operational requirements as the company transitions from development to revenue generation.The latest strategic move focuses on proving economic value rather than just clinical capability. Ventripoint engaged Summit Sciences, a specialized healthcare consulting firm, to develop ROI models that show hospitals exactly what they will save. These models integrate real-world data to demonstrate measurable returns through process improvements, enhanced diagnostic accuracy, and optimized resource allocation."We are excited to partner with Dana and Summit Sciences to elevate our financial modeling capabilities," said Hugh MacNaught, President and CEO of Ventripoint Diagnostics. "Dana's extensive expertise in healthcare transformation, combined with Summit Sciences' proven track record in data-driven consulting, will enable us to deliver even more compelling value propositions to our customers. This initiative underscores our commitment to not only advancing cardiac care through technology but also ensuring that our solutions make strong economic sense for healthcare providers worldwide."Dana Friesen leads Summit Sciences as CEO, bringing more than 15 years of experience in financial analysis and ROI optimization within the medical device sector. The firm has delivered billions in cumulative savings for clinical partners. Friesen's work with indigenous health networks aligns with Ventripoint's expansion into underserved markets.The company announced a partnership with Nisga'a Valley Health Authority establishing a model for delivering advanced cardiac imaging to remote and Indigenous communities. The collaboration uses a hub-and-spoke design where local providers acquire ultrasound scans and transmit them digitally to specialists at a central hub for rapid interpretation.Ventripoint appointed David Swetlow as Chief Financial Officer. Swetlow brings more than 15 years of senior management experience from high-growth medical technology companies including Sernova, Ondine, Protox, HealthPricer, and QLT. Management views the appointment as a key step in executing a commercial strategy designed to accelerate market adoption and drive revenue growth.The company also issued a corporate update detailing its Device-as-a-Service subscription model. Management believes this approach shortens sales cycles and builds recurring revenue streams while making the technology accessible to more healthcare facilities without requiring large upfront capital investments.CONTINUED… Read this and more news for VentriPoint Diagnostics at:  https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripointIn other industry developments and happenings in the market include:Butterfly Network (NYSE: BFLY) announced plans to release its Beam Steering API in first half 2026, marking the first time third-party developers will access digital 3D beam steering capabilities for AI-enabled ultrasound applications. The API leverages the company's proprietary semiconductor chip technology featuring approximately 9,000 elements that enable software-defined beam steering with off-axis tilt up to 20 degrees without mechanical motion."As the first to offer digital beam steering access to developers, Butterfly Network is changing the game for imaging AI, empowering more advanced tools that simplify image acquisition," said Steve Cashman, Chief Business Officer of Butterfly Network. "As our platform evolves, Butterfly partners gain access to more of our core imaging capabilities, allowing them to build richer, more sophisticated applications."The planned SDK access will support advanced imaging workflows across multiple presets including abdominal, cardiac, obstetric, musculoskeletal, vascular, and lung imaging. Butterfly Network continues expanding its Butterfly Garden and Ultrasound-on-Chip co-development programs, with availability and technical details dependent on ongoing development, regulatory considerations, and partner agreements to democratize ultrasound technology across clinical settings.RadNet (NASDAQ: RDNT) has acquired Radiology Regional, a division of LucidHealth serving Southwest Florida, expanding RadNet's footprint to 13 locations across Naples, Cape Coral, Fort Myers, Port Charlotte and Sarasota. The acquisition adds approximately 400 employees and 44 contracted radiologists to RadNet's operations, with the transaction projected to contribute approximately $100 million in revenue during 2026."RadNet is proud to enter a dynamic region of Florida and build on Radiology Regional's well-trusted history," said Steve Forthuber, President and CEO of Eastern Operations for RadNet. "Through our clinical excellence, operations expertise and AI-powered digital health solutions, RadNet intends to bring accessible and affordable leading-edge patient care, population health screening programs and a focus on early detection of disease to the communities of Southwest Florida."The 13 acquired centers provide comprehensive multi-modality imaging including MRI, CT, PET/CT, mammography, ultrasound and X-ray services built over Radiology Regional's half-century history. RadNet plans to deploy its DeepHealth AI-powered innovations across the acquired facilities to increase clinical accuracy, streamline imaging processes and improve patient experience in the rapidly growing Southwest Florida market.Nanox Imaging (NASDAQ: NNOX) has expanded operations across Serbia, Montenegro, and Bosnia and Herzegovina through a strategic collaboration with Adriamed d.o.o. Beograd, a Belgrade-based medical device distributor. The engagement brings the Nanox.ARC multi-source digital tomosynthesis system to healthcare providers throughout the Western Balkans region."We are building momentum in Europe through this strategic collaboration with Adriamed, whose expertise and regional reach will support our commercial expansion in the Western Balkans," said Erez Meltzer, CEO and Acting Chairman of Nanox Imaging. "Our strategy centers on expanding access to cost-effective imaging solutions through established regional partners."Under the agreement, Adriamed becomes Nanox Imaging's exclusive partner for the Nanox.ARC system and related services across the three-country region. The collaboration follows recent distribution agreements in Greece, Romania, Czech Republic and France as Nanox Imaging continues building its European commercial footprint.OneMedNet (NASDAQ: ONMD) has supported FDA 510(k) clearance of mlHealth 360's Scaida BrainCT-ICH, an AI-powered software solution for rapid detection of intracranial hemorrhage from head CT scans. OneMedNet's regulatory-grade Real-World Data spanning longitudinal electronic medical records, diagnostic imaging, and clinical reports played a critical role in supporting model development, validation, and regulatory submission for the software that analyzes head CT images in approximately 5.97 seconds."We are proud to collaborate with our premier partner mlHealth 360 and to support their efforts in advancing patient care through clinically impactful AI," said Aaron Green, CEO and President of OneMedNet. "Seeing OneMedNet's regulatory-grade Real-World Data—enriched with medical imaging and EMR context—contribute directly to an FDA-cleared solution reinforces the value of high-quality data in accelerating meaningful innovation."This milestone validates OneMedNet's position as a leading Real-World Data provider as life science and AI companies increasingly rely on OneMedNet to support FDA submissions. The depth, diversity, and quality of OneMedNet's curated imaging and clinical datasets enabled mlHealth 360 to access fit-for-purpose data while maintaining data integrity and regulatory compliance.Article Source: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripointCONTACT:USA NEWS GROUP
info @acblanke1DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Ventripoint Diagnostics Ltd. advertising or digital media, but the owner/operators of MIQ also co-owns Baystreet.ca Media Corp. ("BAY") There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.SOURCES:1.   https://www.grandviewresearch.com/industry-analysis/medical-imaging-systems-market
2.   https://www.bloomberg.com/news/articles/2026-01-23/new-potent-cancer-treatments-are-raising-heart-risks-for-survivors
3.   https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-in-cardiology-market-report
4.   https://www.jacc.org/doi/10.1016/j.jaccao.2025.08.001
5.   https://link.springer.com/article/10.1186/s40959-016-0014-2 Logo - https://mma.prnewswire.com/media/2838876/5737507/USA_News_Group_Logo.jpg 



View original content to download multimedia:https://www.prnewswire.com/news-releases/ai-medical-imaging-revolution-software-native-tech-disrupts-45b-market-302671377.html

Original: AI Medical Imaging Revolution: Software-Native Tech Disrupts $45B Market

RDNT new 52 week high

This company's management has no clue what they're doing. Terrible management of available monies. With the coming reimbursement cuts in 2021, they desperately need a change in their management.

RadNet furloughing rad techs in Baltimore (despite Berger stating there were no plans to decrease staff)

Nice!!

Basement prices all throughout, you just have to do a little digging to find these gems. Let’s go!!

It’s time, let’s go!!

RadNet to Install the TULSA-PRO® System for Leading-Edge Customizable, Incision-Free Prostate Treatment
Email Print Friendly Share
January 10, 2020 06:00 ET | Source: RadNet, Inc.
LOS ANGELES, Jan. 10, 2020 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services today reported it has committed to install its first TULSA-PRO® System, an incision-free solution for prostate disease, which was developed to revolutionize treatment for men diagnosed with prostate cancer.

Combining real-time Magnetic Resonance Imaging (MRI) with robotically-driven directional thermal ultrasound and closed-loop temperature feedback control software, the TULSA-PRO® System delivers transurethral prostate tissue ablation of whole-gland or partial gland prostate tissue. The system is designed to be customizable to the individual treatment needs of each patient. It is an incision-free, radiation-free ablation that simultaneously protects the urethra and rectum with water cooling, which is designed to preserve men’s functional abilities.

The procedure has been cleared by the FDA and will be initially performed on an outpatient basis in a newly constructed, state-of-the-art 3T MRI room and recovery suite at RadNet’s Liberty Pacific Advanced Imaging location in West Hills, California (held within a joint venture with Cedars-Sinai Medical Center) beginning in the later part of the first quarter. Following its introduction at Liberty Pacific, RadNet plans to expand the TULSA-PRO program to centers located in West Los Angeles and in the Orange County/Irvine areas.

Under the stewardship of Dr. Robert Princenthal, RadNet has been on the forefront of prostate cancer care and was one of the first radiology practices in the U.S. to establish a dedicated prostate MRI program.

Dr. Howard Berger, Chairman and Chief Executive Officer of RadNet, noted, “Prostate cancer is the most prevalent cancer afflicting men in the United States. For many years, RadNet has been focused on investing in and deploying technologies aimed at the early detection and diagnosis of prostate disease. The TULSA-PRO® System expands RadNet into the treatment of this disease process. In our facilities, beginning with West Hills, urological surgeons will be utilizing this device along with RadNet’s MRI technology to treat men with prostate disease, while minimizing negative side effects and preserving normal functionality.”

About RadNet, Inc.

RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 340 owned and/or operated outpatient imaging centers. RadNet's core markets include California, Maryland, Delaware, New Jersey and New York. In addition, RadNet provides radiology information technology solutions, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technicians, RadNet has a total of over 8,000 employees. For more information, visit www.radnet.com.

About Profound Medical (Developer of TULSA-PRO)

Profound Medical (NASDAQ:PROF; TSX:PRN) develops and markets customizable, incision-free therapies for the ablation of diseased tissue. Profound is commercializing TULSA-PRO®, a transurethral prostate tissue ablation system that combines real-time Magnetic Resonance Imaging (MRI) with robotically-driven directional thermal ultrasound and closed-loop temperature feedback control software to deliver predictable physician prescribed ablation of whole-gland or partial prostate tissue. The TULSA-PRO® system is designed to provide customizable and predictable, incision-free and radiation-free prostate ablation while actively protecting the urethra and rectum with water cooling to preserve men’s functional abilities. For more information, visit http://www.profoundmedical.

CONTACTS:

RadNet, Inc.
Mark Stolper, 310-445-2800
Executive Vice President and Chief Financial Officer

Related Articles
More articles issued by RadNet, Inc.
More articles related to:
Company Announcement

News: $RDNT Why RadNet Is Shooting Higher Today

Shares of RadNet (NASDAQ: RDNT) , a company focused on outpatient diagnostic imaging services , jumped 14% as of 2:40 p.m. EST on Friday. The double-digit move is traceable to the news that the company is joining a small-cap index. S&P Dow Jones Indices announced today that RadNet is re...

Read the whole news RDNT - Why RadNet Is Shooting Higher Today

News: $RDNT RadNet Reports Record Fourth Quarter and Full Year 2018 Results and Releases 2019 Financial Guidance

For the fourth quarter of 2018, RadNet reports Total Net Revenue (“Revenue”) of $257.2 million and Adjusted EBITDA ([1]) of $46.2 million; Adjusted EBITDA (1)  includes adjustments as a result of substantial gains and losses from changes in the organization of east coas...

Got this from https://marketwirenews.com/news-releases/radnet-reports-record-fourth-quarter-and-full-year-2018-results-and-releases-2019-financial-guidance-7846504.html

$RDNT recent news/filings

bullish 6.74

## source: finance.yahoo.com

Tue, 10 Nov 2015 13:35:00 GMT ~ How it All Plays Out - Research on Vocera Communications, Curis, RadNet and Tandem Diabetes Care

[Accesswire] - NEW YORK, NY / ACCESSWIRE / November 10, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Vocera Communications ...

read full: http://finance.yahoo.com/news/plays-research-vocera-communications-curis-133500120.html
*********************************************************

Tue, 10 Nov 2015 11:01:42 GMT ~ RADNET, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits


read full: http://biz.yahoo.com/e/151110/rdnt8-k.html
*********************************************************

Mon, 09 Nov 2015 22:00:07 GMT ~ RADNET, INC. Files SEC form 10-Q, Quarterly Report


read full: http://biz.yahoo.com/e/151109/rdnt10-q.html
*********************************************************

Mon, 09 Nov 2015 17:06:46 GMT ~ Edited Transcript of RDNT earnings conference call or presentation 9-Nov-15 3:30pm GMT


read full: http://finance.yahoo.com/news/edited-transcript-rdnt-earnings-conference-170646241.html
*********************************************************

$RDNT charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$RDNT company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/RDNT/company-info
Ticker: $RDNT
OTC Market Place: Not Available
CIK code: 0000790526
Company name: RadNet, Inc.
Company website: http://www.radnet.com
Incorporated In: DE, USA

$RDNT share structure

## source: otcmarkets.com

Market Value: $292,588,504 a/o Nov 11, 2015
Shares Outstanding: 44,466,338 a/o Aug 07, 2015
Float: Not Available
Authorized Shares: 200,000,000 a/o Nov 28, 2006
Par Value: 0.0001

$RDNT extra dd links

Company name: RadNet, Inc.
Company website: http://www.radnet.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=RDNT+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=RDNT+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=RDNT+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/RDNT/news - http://finance.yahoo.com/q/h?s=RDNT+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/RDNT/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/RDNT/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=RDNT+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/RDNT
DTCC (dtcc.com): http://search2.dtcc.com/?q=RadNet%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=RadNet%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=RadNet%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.radnet.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.radnet.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.radnet.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/RDNT
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000790526&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/RDNT/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/RDNT/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=RDNT&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=RDNT
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/RDNT/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=RDNT+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=RDNT+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=RDNT
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=RDNT
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=RDNT+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/RDNT/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=RDNT+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/RDNT.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=RDNT
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/RDNT/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/RDNT
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/RDNT
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/RDNT:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=RDNT
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=RDNT



$RDNT DD Notes ~ http://www.ddnotesmaker.com/RDNT

Looks like the dumping is over. Time to buy!

The chart don't lie!
http://quotes.wsj.com/RDNT

$RDNT DD Notes ~ http://www.ddnotesmaker.com/RDNT

bullish
price channel scan
http://stockcharts.com/school/doku.php?id=chart_school:chart_analysis:chart_patterns:price_channel_continuation
http://www.online-stock-trading-guide.com/channeling-stocks.html


$RDNT recent news/filings

## source: finance.yahoo.com

Fri, 24 Oct 2014 18:21:51 GMT ~ RadNet, Inc. Announces Date of Its Third Quarter 2014 Financial Results Conference Call

[GlobeNewswire] - LOS ANGELES -- RadNet, Inc. , a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announced today ...

read full: http://finance.yahoo.com/news/radnet-inc-announces-date-third-182151454.html
*********************************************************

Fri, 17 Oct 2014 14:00:00 GMT ~ RadNet (RDNT) Flagged As Strong On High Volume


read full: http://www.thestreet.com/story/12918222/1/radnet-rdnt-flagged-as-strong-on-high-volume.html?puc=yahoo&cm_ven=YAHOO
*********************************************************

Thu, 16 Oct 2014 11:22:43 GMT ~ Can the Rally in RadNet (RDNT) Shares Continue?


read full: http://finance.yahoo.com/news/rally-radnet-rdnt-shares-continue-112243800.html
*********************************************************

Thu, 09 Oct 2014 15:47:49 GMT ~ David Stoller, MD, to Host Upcoming CME Course in Orthopaedic Imaging

[GlobeNewswire] - LOS ANGELES -- RadNet, Inc., a leading provider of high-quality, cost-effective diagnostic imaging services through a national network of 251 owned and/or operated outpatient imaging centers, announced ...

read full: http://finance.yahoo.com/news/david-stoller-md-host-upcoming-154749954.html
*********************************************************

Tue, 16 Sep 2014 13:32:40 GMT ~ Madison Radiology Medical Group Implements eRAD RIS

[GlobeNewswire] - GREENVILLE, S.C. -- eRAD, a subsidiary of RadNet, Inc. , a leading provider of standards-based, web-centric radiology image and data management solutions, announced today that Madison Radiology Medical ...

read full: http://finance.yahoo.com/news/madison-radiology-medical-group-implements-133240551.html
*********************************************************


$RDNT charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$RDNT company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/RDNT/company-info
Ticker: $RDNT
OTC Market Place: Not Available
CIK code: 0000790526
Company name: RadNet, Inc.
Company website: http://www.radnet.com
Incorporated In: DE, USA


$RDNT share structure

## source: otcmarkets.com

Market Value: $396,875,445 a/o Oct 31, 2014
Shares Outstanding: 42,674,779 a/o Aug 07, 2014
Float: Not Available
Authorized Shares: 200,000,000 a/o Nov 28, 2006
Par Value: 0.0001
$RDNT extra dd links

Company name: RadNet, Inc.
Company website: http://www.radnet.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=RDNT+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=RDNT+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=RDNT+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/RDNT/news - http://finance.yahoo.com/q/h?s=RDNT+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/RDNT/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/RDNT/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=RDNT+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/RDNT
DTCC (dtcc.com): http://search2.dtcc.com/?q=RadNet%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=RadNet%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=RadNet%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.radnet.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.radnet.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.radnet.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/RDNT
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000790526&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/RDNT/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/RDNT/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=RDNT&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=RDNT
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/RDNT/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=RDNT+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=RDNT+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=RDNT
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=RDNT
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=RDNT+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/RDNT/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=RDNT+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/RDNT.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=RDNT
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/RDNT/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/RDNT
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/RDNT
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/RDNT:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=RDNT
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=RDNT



$RDNT DD Notes ~ http://www.ddnotesmaker.com/RDNT

$RDNT DD Notes ~ http://www.ddnotesmaker.com/RDNT

bullish

$RDNT recent news/filings

## source: finance.yahoo.com

Wed, 08 Oct 2014 12:25:00 GMT ~ 3 Breakout Stocks Under $10 for Your Watch List


read full: http://www.thestreet.com/story/12906535/1/3-breakout-stocks-under-10-for-your-watch-list.html?puc=yahoo&cm_ven=YAHOO
*********************************************************

Tue, 16 Sep 2014 13:32:40 GMT ~ Madison Radiology Medical Group Implements eRAD RIS

[GlobeNewswire] - GREENVILLE, S.C. -- eRAD, a subsidiary of RadNet, Inc. , a leading provider of standards-based, web-centric radiology image and data management solutions, announced today that Madison Radiology Medical ...

read full: http://finance.yahoo.com/news/madison-radiology-medical-group-implements-133240551.html
*********************************************************

Fri, 12 Sep 2014 11:47:59 GMT ~ Strength Seen in RadNet (RDNT): Stock Gains 11.2%


read full: http://finance.yahoo.com/news/strength-seen-radnet-rdnt-stock-114759941.html
*********************************************************

Tue, 09 Sep 2014 13:39:09 GMT ~ AMIC Chicago Implements eRAD PACS Cloud Solution

[GlobeNewswire] - GREENVILLE, S.C. -- Advanced Medical Imaging Center (AMIC), a multi-modality imaging center with two locations in downtown Chicago, implemented eRAD PACS to leverage its cloud-based worklist and to streamline ...

read full: http://finance.yahoo.com/news/amic-chicago-implements-erad-pacs-133909428.html
*********************************************************

Tue, 19 Aug 2014 17:04:31 GMT ~ RADNET, INC. Financials


read full: http://finance.yahoo.com/q/is?s=rdnt
*********************************************************


$RDNT charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$RDNT company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/RDNT/company-info
Ticker: $RDNT
OTC Market Place: Not Available
CIK code: 0000790526
Company name: RadNet, Inc.
Company website: http://www.radnet.com
Incorporated In: DE, USA


$RDNT share structure

## source: otcmarkets.com

Market Value: $318,780,599 a/o Oct 08, 2014
Shares Outstanding: 42,674,779 a/o Aug 07, 2014
Float: Not Available
Authorized Shares: 200,000,000 a/o Nov 28, 2006
Par Value: 0.0001
$RDNT extra dd links

Company name: RadNet, Inc.
Company website: http://www.radnet.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=RDNT+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=RDNT+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=RDNT+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/RDNT/news - http://finance.yahoo.com/q/h?s=RDNT+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/RDNT/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/RDNT/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=RDNT+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/RDNT
DTCC (dtcc.com): http://search2.dtcc.com/?q=RadNet%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=RadNet%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=RadNet%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.radnet.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.radnet.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.radnet.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/RDNT
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000790526&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/RDNT/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/RDNT/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=RDNT&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=RDNT
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/RDNT/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=RDNT+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=RDNT+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=RDNT
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=RDNT
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=RDNT+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/RDNT/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=RDNT+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/RDNT.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=RDNT
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/RDNT/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/RDNT
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/RDNT
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/RDNT:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=RDNT
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=RDNT



$RDNT DD Notes ~ http://www.ddnotesmaker.com/RDNT

$RDNT recent news/filings

bullish

## source: finance.yahoo.com

Thu, 14 Aug 2014 15:15:00 GMT ~ RadNet Inc Stock Upgraded (RDNT)


read full: http://www.thestreet.com/story/12845045/1/radnet-inc-stock-upgraded-rdnt.html?puc=yahoo&cm_ven=YAHOO
*********************************************************

Mon, 11 Aug 2014 11:30:34 GMT ~ Strength Seen in RadNet (RDNT): Stock Soars 20.8%


read full: http://finance.yahoo.com/news/strength-seen-radnet-rdnt-stock-113034280.html
*********************************************************

Mon, 11 Aug 2014 10:00:35 GMT ~ RADNET, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits


read full: http://biz.yahoo.com/e/140811/rdnt8-k.html
*********************************************************

Fri, 08 Aug 2014 11:07:03 GMT ~ Q2 2014 RadNet Inc Earnings Release - Time Not Supplied


read full: http://biz.yahoo.com/research/earncal/20140808.html?t=rdnt
*********************************************************

Fri, 08 Aug 2014 10:00:00 GMT ~ RadNet Reports Record Second Quarter Financial Results and Adjusts Upwards 2014 Guidance Ranges for Revenue and Adjusted EBITDA(1)

[GlobeNewswire] - LOS ANGELES -- RadNet, Inc. , a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 251 owned and/or operated outpatient imaging ...

read full: http://finance.yahoo.com/news/radnet-reports-record-second-quarter-100000753.html
*********************************************************


$RDNT charts

basic chart ## source: stockcharts.com



basic chart ## source: eoddata.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$RDNT company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/RDNT/company-info
Ticker: $RDNT
OTC Market Place: Not Available
CIK code: 0000790526
Company name: RadNet, Inc.
Company website: http://www.radnet.com
Incorporated In: DE, USA


$RDNT share structure

## source: otcmarkets.com

Market Value: $283,894,662 a/o Aug 14, 2014
Shares Outstanding: 41,749,215 a/o May 07, 2014
Float: Not Available
Authorized Shares: 200,000,000 a/o Nov 28, 2006
Par Value: 0.0001
$RDNT extra dd links

Company name: RadNet, Inc.
Company website: http://www.radnet.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=RDNT+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=RDNT+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=RDNT+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/RDNT/news - http://finance.yahoo.com/q/h?s=RDNT+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/RDNT/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/RDNT/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=RDNT+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/RDNT
DTCC (dtcc.com): http://search2.dtcc.com/?q=RadNet%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=RadNet%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=RadNet%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.radnet.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.radnet.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.radnet.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/RDNT
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000790526&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/RDNT/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/RDNT/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=RDNT&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=RDNT
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/RDNT/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=RDNT+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=RDNT+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=RDNT
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=RDNT
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=RDNT+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/RDNT/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=RDNT+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/RDNT.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=RDNT
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/RDNT/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/RDNT/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/RDNT
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/RDNT
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/RDNT:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=RDNT
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=RDNT



$RDNT DD Notes ~ http://www.ddnotesmaker.com/RDNT

RadNet, Inc. [$RDNT] due diligence

bullish


$RDNT

DD Notes ~ http://www.ddnotesmaker.com/RDNT

##### recent news/filings ~ source: finance.yahoo.com

Thu, 29 May 2014 18:21:00 GMT ~ RadNet, Inc. to Present at the Jefferies 2014 Global Healthcare Conference on June 2, 2014
[GlobeNewswire] - LOS ANGELES -- RadNet, Inc. , a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced ...
read full: http://finance.yahoo.com/news/radnet-inc-present-jefferies-2014-182100723.html
*********************************************************

Wed, 21 May 2014 11:10:27 GMT ~ Will RadNet (RDNT) Continue to Surge Higher?
read full: http://finance.yahoo.com/news/radnet-rdnt-continue-surge-higher-111027542.html
*********************************************************

Tue, 20 May 2014 17:44:20 GMT ~ Nasdaq stocks posting largest percentage increases
[AP] - A look at the 10 biggest percentage gainers on Nasdaq at the close of trading: InterCloud Systems rose 22.9 percent to $12.90. Bind Therapeutics rose 12.0 percent to $15.40. RiceBran Tech rose 10.6 percent ...
read full: http://sg.finance.yahoo.com/news/nasdaq-stocks-posting-largest-percentage-220404274--finance.html
*********************************************************

Tue, 20 May 2014 17:04:18 GMT ~ RADNET, INC. Financials
read full: http://finance.yahoo.com/q/is?s=rdnt
*********************************************************

Mon, 12 May 2014 13:05:13 GMT ~ RadNet Touches New 52-Week High
read full: http://finance.yahoo.com/news/radnet-touches-52-week-high-130513458.html
*********************************************************

##### chart ~ source: stockcharts.com



##### chart ~ source: eoddata.com



##### company info ~ source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/RDNT/company-info
Ticker: $RDNT
OTC Market Place: Not Available
CIK code: 0000790526
Company name: RadNet, Inc.
Company website: http://www.radnet.com
Incorporated In: DE, USA

##### extra dd links

Edgar filings: http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000790526&owner=exclude&count=40
Latest filings: http://www.otcmarkets.com/stock/RDNT/filings
Latest financials: http://www.otcmarkets.com/stock/RDNT/financials
Latest news: http://www.otcmarkets.com/stock/RDNT/news - http://finance.yahoo.com/q/h?s=RDNT+Headlines

Major holdings: http://data.cnbc.com/quotes/RDNT/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=RDNT+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/RDNT.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=RDNT

RegSho: http://www.regsho.com/tools/symbol_stats.php?sym=RDNT&search=search

DTCC: http://search2.dtcc.com/?q=RadNet%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&q=RadNet%2C+Inc.
Corporation WIKI: http://www.corporationwiki.com/search/results?term=RadNet%2C+Inc.&x=0&y=0
WHOIS: http://whois.domaintools.com/http://www.radnet.com
Alexa: http://www.alexa.com/siteinfo/http://www.radnet.com#
Corporate website internet archive: http://web.archive.org/web/*/http://www.radnet.com

Short Sales: http://www.otcmarkets.com/stock/RDNT/short-sales
Insider Disclosure: http://www.otcmarkets.com/stock/RDNT/insider-transactions
Research Reports: http://www.otcmarkets.com/stock/RDNT/research
Historical Prices: http://finance.yahoo.com/q/hp?s=RDNT+Historical+Prices
Basic Tech. Analysis: http://finance.yahoo.com/q/ta?s=RDNT+Basic+Tech.+Analysis
Company Profile: http://finance.yahoo.com/q/pr?s=RDNT+Profile
Key Statistics: http://finance.yahoo.com/q/ks?s=RDNT+Key+Statistics
Industry: http://finance.yahoo.com/q/in?s=RDNT+Industry
Insider Roster: http://finance.yahoo.com/q/ir?s=RDNT+Insider+Roster
Income Statement: http://finance.yahoo.com/q/is?s=RDNT
Balance Sheet: http://finance.yahoo.com/q/bs?s=RDNT
Cash Flow: http://finance.yahoo.com/q/cf?s=RDNT+Cash+Flow&annual
Market Watch: http://www.marketwatch.com/investing/stock/RDNT
Bloomberg: http://www.bloomberg.com/quote/RDNT:US
Morningstar: http://quotes.morningstar.com/stock/s?t=RDNT
Bussinessweek: http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=RDNT
Barchart: http://www.barchart.com/quotes/stocks/RDNT
OTC Short Report: http://otcshortreport.com/index.php?index=RDNT
Investopedia: http://www.investopedia.com/markets/stocks/RDNT/?wa=0

http://www.pennystocktweets.com/stocks/profile/RDNT

##### last known share structure ~ source: otcmarkets.com

Market Value: $264,690,023 a/o Jun 04, 2014
Shares Outstanding: 41,749,215 a/o May 07, 2014
Float: Not Available
Authorized Shares: 200,000,000 a/o Nov 28, 2006
Par Value: 0.0001

##### business description ~ source: otcmarkets.com



DD Notes ~ http://www.ddnotesmaker.com/RDNT
d

TERRIBLE ARTICLE OUT!!!

http://seekingalpha.com/article/2235103-radnet-likely-to-lose-half-its-value-with-415-million-debt-due-in-2018-2_50-target

I have more shares i'm trying to short at 6.27 Doesn't look like I'll get em anymore :(

RJ- I'm going to go short here on this stock today too. Obvious dump coming...

http://finance.yahoo.com/q/it?s=RDNT+Insider+Transactions

INSIDERS HAVE BEGUN SELLING AS OF MAY 13

Enjoying the upside run!

I love that this board is silent and this baby is runnin. Bet this gets talkative when the squeeze is on

If this locks out @ $2.60 or above you better expect to see a bull raid on this mother

Im thinking closing price is going to be $2.54

these guys got a lot of cash on hand im thinking they may try to gain some more acquisitions, time to short AIQ too overweight.

Bluemountain increases shares in RDNT AGAIN!

http://archive.fast-edgar.com//20140130/AI2ZB22CZM2RLJZZ2H2G2ZXOI552ZZ22ZS62/

I got the patients and patience part, had to look up that last one..?? Hmmmmm not good...LOL

Oh well, I'm about even with the comission, and plenty of patience..!! Only threw a couple hundred at it, will be happy with $250 profit. I've got another year before I need a tax loss

Exercise in patients, patience & perfidy...

This is a real lively board...
Must be a sign of the times of what obamacare is going to do to the healthcare industry.
Anyway picked up a few shares @ $1.65 for fun!

Morgan Keegan is out with its report today on RadNet (NASDAQ: RDNT), raising its PT from $4.30 to $5.15.

In a note to clients, Morgan Keegan writes, "We are modestly lowering our 2011 adjusted EBITDA estimate for RadNet from $118 million to $115 million and our 2012 estimate from $126 million to $124 million. However, we are raising our price target from $4.30 to $5.15 based on a multiple of 6.5x EV/EBITDAR."

Morgan Keegan maintains Outperform on RDNT.


Source: http://www.benzinga.com/analyst-ratings/analyst-color/11/05/1086215/update-morgan-keegan-raises-pt-on-radnet-to-5-15-rdnt#ixzz1MWchatXI

Oh, the ChutzpaH! Voting to amend incentive plan to 30% of shares! Think these guys forgot they are publicly traded????

Paying $625K to very spreadout prez & $100k fees to directors for incredibly lackluster performance.

Public Utilities are supposed to compensated on the size of their assets, not imaging providers.

Chart looks ready to break-out, took a starter position today. Will add annotations later today:

Morgan Keegan has released a report, in which the Price Target of RadNet, Inc. (NASDAQ: RDNT) was raised from $3.40 to $4.30.

Morgan Keegan reports, “We are raising our 2011 adjusted EBITDA estimate for RadNet from $114 million to $118 million and our 2012 estimate from $125 million to $126 million. Accordingly, we are raising our price target from $3.40 to $4.30.”


Source: http://www.benzinga.com/analyst-ratings/analyst-color/11/03/923258/morgan-keegan-raises-pt-on-rdnt-to-4-30#ixzz1GaRvmqMD

NYTimes - "CT Scans Cut Lung Cancer Deaths"

Finally some positive press...!!

According to a recent government-financed NIH study, its been determined that annual CT scans of current and former heavy smokers reduced their risk of death from lung cancer by 20% and that these cancer doctors predict that the study's results would soon "lead to widespread use of CT scans" for current smokers who have a 1 in 10 chance of contracting lung cancer.

http://www.nytimes.com/2010/11/05/health/research/05cancer.html

The article goes on to say that the federal Medicare program "will soon reconsider paying for these CT lung screens" instead of the patients having to pay for the scans themselves, and that these CT scans also "helped to detect other life-threatening diseases besides lung cancer."

And according to the American Heart Association, there are currently an estimated 24.8 million men and 21.1 million women in the United States who are smokers (that's unbelievable, and very sad), and we know that lung cancer claims about 157,000 lives each year (just terrible).

I believe these recent findings will benefit RDNT in a meaningful way, and could create significant revenue opportunities going forward.

As we know, RDNT is one of the largest multi-modality imaging companies in the country with one of the largest fleets of imaging equipment, including CT scans. Should the federal government begin to pay for annual CT scans for these current and former smokers, RDNT could not be better positioned to capitalize on these new recent developments IMHO.

As the study suggests, at least for lung cancer, "spending more on tests saves lives."

What a great opportunity for RDNT and its shareholders.

What's the "bear" story on RDNT

Timothy, great call last month on RDNT. It looks like the stock is down around 25% since your short-bias post.

I was just wondering if you could share your "bear" case with everyone. I think that would be helpful.

Thanks

Timothy Sykes short-biased on RDNT

http://www.timothysykes.com/news/13959-8-hot-penny-stock-winners-to-watch/

up 32% today and bottomed 2 days ago...should be strong again all year

keeps getting stronger

RadNet, Inc. Approved for Listing on the NASDAQ Global Market

LOS ANGELES, Feb 13, 2007 (BUSINESS WIRE) -- RadNet, Inc. (OTCBB:RDNT), a leading national provider of high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, announced today that The NASDAQ Stock Market ("NASDAQ") has approved its application for listing on The NASDAQ Global Market. RadNet expects to commence trading on the NASDAQ Global Market under its new ticker symbol "RDNT," effective at market opening on Wednesday, February 14, 2007. Until that time, RadNet's stock will continue to trade on The OTC Bulletin Board under the symbol "RDNT.OB."
Dr. Howard Berger, President and Chief Executive Officer, commented, "We are extremely pleased that our listing application has been approved. A NASDAQ listing is a significant milestone for our company, and highlights our growth and continued commitment to enhance shareholders' value. Trading on NASDAQ should create a more orderly and liquid market for the Company's securities and increase the visibility and profile of the Company in the investment community."

About RadNet, Inc.

RadNet, Inc., is a national market leader providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers. For its fiscal year ended October 31, 2006, RadNet and its subsidiaries (including Radiologix for the 12 months ended December 31, 2006) performed 2,336,814 diagnostic imaging procedures. At October 31, 2006, together with Beverly Radiology Medical Group and Radiologix, and inclusive of full-time and per diem employees, technicians and radiologists, the Company had a total of 3,911 employees. For more information, visit www.radnet.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning the benefits of listing on the NASDAQ Global Market, anticipated future financial and operating performance, and RadNet's ability to continue to grow the business by generating patient referrals and contracts with radiology practices, recruiting and retaining technologists, and receiving third-party reimbursement for diagnostic imaging services, as well as RadNet's financial guidance, are forward-looking statements within the meaning of the Safe Harbor. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties which may cause RadNet's actual results to differ materially from the statements contained herein. These risks and uncertainties include, among others, those set forth in RadNet's reports filed with the SEC, including its annual report on Form 10-K for the year ended October 31, 2006, and the joint proxy statement/prospectus dated October 20, 2006. Undue reliance should not be placed on forward-looking statements, especially guidance on future financial performance, which speaks only as of the date it is made. RadNet undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

SOURCE: RadNet, Inc.



CONTACT: RadNet, Inc.
Mark Stolper, Chief Financial Officer, 310-445-2800
or
Integrated Corporate Relations, Inc.
John Mills, 310-954-1105
jmills@icrinc.com

hopefully going on the nasdaq soon

keeps on going and going and going ......

been moving up watch this one

enjoy all

RadNet Inc aiming for nasdaq listing